Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T21:34:05.491Z.
Calculation as of: 2026-10-06T21:34:05.491Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 970d877bc7db717cbed859036c212f4e9de57f4ce891843b12d0c27006da4837
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Seaport Therapeutics, Inc. Common Stock
Market Cap
$929.83M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$921.06M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$914.73M
Price/OCF Ratio
12.74
TTM Avg
11.45
3Y Avg
13.28
5Y Avg
14.23
Market Cap
$887.99M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Seaport Therapeutics, Inc. Common Stock (SPTX) | $929.83M | N/A | N/A | N/A | N/A |
| Kura Oncology, Inc. (KURA)vs › | $934.79M | N/A | 6.63 | 6.62 | 6.62 |
| CeriBell, Inc. (CBLL)vs › | $923.53M | N/A | N/A | N/A | N/A |
| MoonLake Immunotherapeutics (MLTX)vs › | $921.06M | N/A | N/A | N/A | N/A |
| HealthStream, Inc. (HSTM)vs › | $914.73M | 12.74 | 11.45 | 13.28 | 14.23 |
| Savara Inc. (SVRA)vs › | $952.91M | N/A | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $953.81M | N/A | N/A | N/A | N/A |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $887.99M | N/A | N/A | N/A | N/A |
| Bioventus Inc. (BVS)vs › | $887.50M | 9.16 | 9.21 | 23.47 | 25.52 |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.93M | 5.19 | 6.80 | 7.11 | 11.19 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
